Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase III Lyma trial of rituximab maintenance after ASCT in mantle cell lymphoma

Bertrand Coiffier • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Cisplatin Cytarabine Dexamethasone

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphom

More from Bertrand Coiffier

Understanding biosimilars
2:40
Understanding biosimilars
Bertrand Coiffier • 22 Jun 2017
Why we need novel strategies for diffuse large B-cell lymphoma
3:27
Why we need novel strategies for diffuse large B-cell lymphoma
Bertrand Coiffier • 22 Jun 2017
Biosimilars in oncology: EHA 2017 session on rituximab
1:28
Biosimilars in oncology: EHA 2017 session on rituximab
Bertrand Coiffier • 22 Jun 2017
Biosimilars: informing patients and physicians
0:39
Biosimilars: informing patients and physicians
Bertrand Coiffier • 22 Jun 2017

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals